223 related articles for article (PubMed ID: 15173327)
1. GLP-1: target for a new class of antidiabetic agents?
Edwards CM
J R Soc Med; 2004 Jun; 97(6):270-4. PubMed ID: 15173327
[No Abstract] [Full Text] [Related]
2. Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.
Rachman J
Diabet Med; 2004 Jan; 21 Suppl 1():18-20. PubMed ID: 15088933
[No Abstract] [Full Text] [Related]
3. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
4. Incretin mimetics as emerging treatments for type 2 diabetes.
Joy SV; Rodgers PT; Scates AC
Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
[TBL] [Abstract][Full Text] [Related]
5. [The role of incretins. Type 2 diabetes with new beginnings].
MMW Fortschr Med; 2005 Mar; 147(10):48-9. PubMed ID: 15803785
[No Abstract] [Full Text] [Related]
6. [Glucagon-like peptide-1 (GLP-1) receptor].
Taminato T
Nihon Rinsho; 2002 Jul; 60 Suppl 7():535-41. PubMed ID: 12238094
[No Abstract] [Full Text] [Related]
7. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
Meier JJ; Gallwitz B; Nauck MA
BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
Gallwitz B
Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
[TBL] [Abstract][Full Text] [Related]
9. A gut feeling.
Pronsati MP
Adv Nurse Pract; 2004 Aug; 12(8):8. PubMed ID: 15354498
[No Abstract] [Full Text] [Related]
10. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
11. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
Sinclair EM; Drucker DJ
Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875
[TBL] [Abstract][Full Text] [Related]
12. A gut response. The next generation of type 2 drugs.
Kordella T
Diabetes Forecast; 2004 Apr; 57(4):39-42. PubMed ID: 15119299
[No Abstract] [Full Text] [Related]
13. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.
Larsen PJ; Holst JJ
Regul Pept; 2005 Jun; 128(2):97-107. PubMed ID: 15780429
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL; Young AA; Parkes DG
Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
[TBL] [Abstract][Full Text] [Related]
16. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
Garber AJ
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469
[No Abstract] [Full Text] [Related]
17. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
18. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
González C; Beruto V; Keller G; Santoro S; Di Girolamo G
Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
[TBL] [Abstract][Full Text] [Related]
19. [Glucagon-like peptide 1 (GLP-1)].
Parhofer KG
MMW Fortschr Med; 2007 Jun; 149(25-26):41-3. PubMed ID: 17713050
[TBL] [Abstract][Full Text] [Related]
20. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
